Scholar Rock Holding Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SRRK in the last 7 days.
AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.
Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.
The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.
Recent SRRK coverage spans financial news, regulation and insider activity.
In the last 30 days, SRRK insiders filed 6 SEC Form 4 transactions — 6 purchases ($12.0M) and no sales. The most active reporter was AKKARAJU SRINIVAS with 6 filings.
Insider buying suggests confidence and may support the stock price.
Analyst upgrade and higher price target may drive buying interest.
Adds a novel SMA therapy to Scholar Rock's pipeline, potentially driving future sales.
Analyst rating upgrade with a higher price target may attract buying interest.
Analyst hold rating with a higher price target may modestly support the stock.
AlphAI scores every news story that mentions SRRK with an AI model for sentiment and relevance, and aggregates insider trades from Scholar Rock Holding Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.
1 min readTruist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.
1 min readThe FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.
3 min readTruist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK) after a management roadshow, citing confidence in the team and strong demand for its spinal muscular atrophy treatment. The stock trades at $41.40, with analysts' targets ranging from $58 to $84. The company resubmitted a Marketing Authorization Application in the EU, and other analysts have also raised their price targets.
1 min readBarclays' Etzer Darout maintained a Hold rating on Scholar Rock Holding (SRRK) with a $58 price target. The stock closed at $42.20, near its 52-week high. Analysts' consensus for SRRK is Strong Buy with a $69.81 average target. Barclays' Claudia Gaspari kept a Buy rating on Strategy (MSTR) with a $175 target. MSTR closed at $151.47, near its 52-week low. Consensus for MSTR is Strong Buy with a $236 average target.
1 min readRaymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.
1 min readScholar Rock (NASDAQ:SRRK) resubmitted its EU application for apitegromab, a treatment for spinal muscular atrophy, using an alternate fill-finish facility. The company withdrew its previous application due to GMP compliance issues. Scholar Rock anticipates a CHMP opinion in the first half of 2027. Apitegromab is FDA-approved in the U.S. under the brand name ISEMBYLD.
2 min readFour biotech companies are hiring: Scholar Rock (SRRK) has 30 open roles and recently received FDA approval for Isembyld (SMA treatment). Insmed (INSM) has over 100 positions open and is advancing gene therapies for DMD and ALS. Ionis Pharmaceuticals (IONS) has 35 roles available and recently gained FDA approvals for Zanvastro (Alexander disease) and Tryngolza (hypertriglyceridemia). Dyne Therapeutics (DYN) has around 60 open positions and is advancing treatments for DMD and FSHD.
3 min readScholar Rock Holding (SRRK) has two manufacturing facilities ready for regulatory review for its lead SMA therapy, apitegromab, reducing supply risk. The company projects $538.3M revenue and $92.4M earnings by 2029, but faces high launch costs and regulatory risks. Analysts' fair value estimates for SRRK range from $70 to $220.
2 min readScholar Rock Holding (SRRK) reported Q2 2026 results, highlighting $492M in cash and preparations for the U.S. launch of apitegromab by September 30th. The company has two fill-finish facilities ready for approval and is advancing its anti-myostatin pipeline, including Phase 2 trials for SMA and FSHD. Positive interactions with FDA and EMA were noted, with plans for a European launch starting in Germany.
2 min read
